Cheng Jiang

Dr. Cheng Jiang serves as a Professor in the Department of Neuroscience and Experimental Therapeutics at Pennsylvania State University, with dual affiliations at the Penn State Neuroscience Institute and the Center for Cannabis and Natural Product Pharmaceuticals (CCNPP). Her h-index of 39 and 4,644 total citations reflect her significant contributions to cancer research, particularly in the areas of prostate and breast cancer chemoprevention.

Dr. Jiang's research focuses on cellular and molecular signaling mechanisms relevant to cancer prevention. Her work prominently features the identification of herbal chemicals and novel selenium compounds targeting sex hormone signaling pathways involved in breast and prostate cancer development. Her fingerprint analysis reveals expertise across multiple key areas including prostate cancer research (100%), malignant neoplasms (81%), selenium compounds (71%), methylseleninic acid (53%), apoptosis mechanisms (49%), p53 protein pathways (47%), and decursin derivatives (46%).

Analysis of her recent publications (2024-2025) shows a strategic expansion of her research program, maintaining her strong foundation in selenium-based cancer prevention while increasingly incorporating cannabinoid research. Her work demonstrates a clear progression from basic molecular mechanisms toward translational applications, with several publications addressing human clinical trial considerations for novel therapeutic approaches.

Dr. Jiang has established significant collaborative networks as evidenced by her co-authorship patterns across multiple institutions. Her research contributes directly to UN Sustainable Development Goals related to good health and well-being. Notably, Dr. Jiang has profound bilateral hearing loss and specifically prefers email communication with collaborators, demonstrating her commitment to maintaining effective scientific partnerships despite this challenge.

Her laboratory work is centered at the Center for Cannabis and Natural Product Pharmaceuticals, where she leads investigations into natural compounds with therapeutic potential. Current research directions include the development of analytical methods for studying drug interactions, characterization of novel compounds for cancer prevention, and exploration of concentration-dependent effects of cannabinoids on cancer cell growth.